These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9592806)

  • 61. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
    Benfield P; Ward A; Clark BG; Jue SG
    Drugs; 1988 Jun; 35(6):670-84. PubMed ID: 3048975
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients.
    Lane HY; Hu OY; Jann MW; Deng HC; Lin HN; Chang WH
    Psychiatry Res; 1997 Mar; 69(2-3):105-11. PubMed ID: 9109178
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
    Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
    Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Do enzyme inducers modify haloperidol decanoate rate of release?
    Pupeschi G; Agenet C; Levron JC; Barges-Bertocchio MH
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1323-32. PubMed ID: 7863019
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The initial US clinical experience in the management of schizophrenic patients with bromperidol.
    Gardner E
    Acta Psychiatr Belg; 1978; 78(1):134-46. PubMed ID: 347876
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
    Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
    Sutton D; Butler AM; Nadin L; Murray M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Co-administration of sertraline and haloperidol.
    Lee MS; Han CS; You YW; Kim SH
    Psychiatry Clin Neurosci; 1998 Dec; 52 Suppl():S193-8. PubMed ID: 9895145
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.
    Kato K; Yasui-Furukori N; Fukasawa T; Aoshima T; Suzuki A; Kanno M; Otani K
    Ther Drug Monit; 2003 Aug; 25(4):473-7. PubMed ID: 12883232
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
    Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
    J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.